Is Early Conversion to MTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes

Overview

Journal Int J Organ Transplant Med

Date 2017 Aug 23

PMID 28828166

Citations 1

Authors

J Kumar

I Reccia

T Kusano

Affiliations

Soon will be listed here.

Abstract

Background: Immunosuppressive therapies are important parts of renal transplantation.

Objective: To assess the present literature on the effectiveness of early introduction of mTOR inhibitors with or without calcineurin inhibitors (CNI) in renal transplant recipients in terms of renal functioning and graft survival.

Methods: The current literature was reviewed following PROSPERO approval, assessing the role of immunosuppressive agent, mTOR inhibitors as an alternative to CNI within 6 months of renal transplantation by searching PubMed, EMBASE, Cochrane, Crossref, and Scopus.

Results: 6 articles of early withdrawal of CNI and introduction of mTOR inhibitors within 6 months of renal transplantation were sought. Glomerular filtration rate (GFR) and serum creatinine were better in mTOR inhibitor group at 12 months. Biopsy-proven acute rejection (BPAR) was significantly higher in mTOR inhibitor group, though survival was comparable.

Conclusion: On the basis of present literature, the early introduction of mTOR inhibitors causes substantial CNI minimization. The mTOR inhibitors are more favorable due to their complementary mechanism of action and favorable nephrotoxicity profile, better glomerular filtration, and lower serum creatinine with equivalent survival. However, the higher rejection rate may influence the use of these regimens in patients with moderate to high immunological risk.

Citing Articles

Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review.

Kumar J, Reccia I, Virdis F, Podda M, Sharma A, Halawa A World J Transplant. 2021; 11(3):70-86.

PMID: 33816147 PMC: 8009058. DOI: 10.5500/wjt.v11.i3.70.

References

Filler G . Calcineurin inhibitors in pediatric renal transplant recipients. Paediatr Drugs. 2007; 9(3):165-74. DOI: 10.2165/00148581-200709030-00005. View

Kaczmarek I, Zaruba M, Beiras-Fernandez A, Reimann R, Nickel T, Grinninger C . Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. J Heart Lung Transplant. 2013; 32(3):277-84. DOI: 10.1016/j.healun.2012.11.028. View

Silva Jr H, Felipe C, Garcia V, Neto E, Filho M, Contieri F . Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant. 2013; 13(12):3155-63. DOI: 10.1111/ajt.12481. View

Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P . Growing experience with mTOR inhibitors in pediatric solid organ transplantation. Pediatr Transplant. 2013; 17(7):694-706. DOI: 10.1111/petr.12147. View

Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T . Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation. 2009; 87(5):726-33. DOI: 10.1097/TP.0b013e3181963371. View

Rostaing L, Kamar N . mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. J Nephrol. 2010; 23(2):133-42. View

Nashan B . Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. Clin Transplant. 2013; 27 Suppl 25:16-29. DOI: 10.1111/ctr.12156. View

ORiordan E, Orlova T, Mendelev N, Patschan D, Kemp R, Chander P . Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl. 2010; 2(7-8):1025-35. PMC: 4690473. DOI: 10.1002/prca.200780137. View

Nankivell B, Borrows R, Fung C, OConnell P, Chapman J, Allen R . Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004; 78(4):557-65. DOI: 10.1097/01.tp.0000128636.70499.6e. View

10.

Salvadori M, Bertoni E . Is it time to give up with calcineurin inhibitors in kidney transplantation?. World J Transplant. 2013; 3(2):7-25. PMC: 3782241. DOI: 10.5500/wjt.v3.i2.7. View

11.

Flechner S . Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation. 2009; 87(8 Suppl):S1-6. DOI: 10.1097/TP.0b013e3181a059a1. View

12.

Gatault P, Lebranchu Y . Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?. Transplant Res. 2014; 2(Suppl 1):S3. PMC: 3834549. DOI: 10.1186/2047-1440-2-S1-S3. View

13.

Gonzalez-Vilchez F, Vazquez de Prada J, Paniagua M, Gomez-Bueno M, Arizon J, Almenar L . Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?. Int J Cardiol. 2013; 171(1):15-23. DOI: 10.1016/j.ijcard.2013.11.036. View

14.

Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A . Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013; 2013:403280. PMC: 3789319. DOI: 10.1155/2013/403280. View

15.

Lebranchu Y, Thierry A, Toupance O, Westeel P, Etienne I, Thervet E . Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009; 9(5):1115-23. DOI: 10.1111/j.1600-6143.2009.02615.x. View

16.

Guba M, Pratschke J, Hugo C, Kramer B, Nohr-Westphal C, Brockmann J . Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation. 2010; 90(2):175-83. DOI: 10.1097/TP.0b013e3181e11798. View

17.

Heilman R, Younan K, Wadei H, Mai M, Reddy K, Chakkera H . Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation. 2011; 92(7):767-73. DOI: 10.1097/TP.0b013e31822805d7. View

18.

Gullestad L, Iversen M, Mortensen S, Eiskjaer H, Riise G, Mared L . Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89(7):864-72. DOI: 10.1097/TP.0b013e3181cbac2d. View

19.

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U . Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011; 377(9768):837-47. DOI: 10.1016/S0140-6736(10)62318-5. View

20.

Hocker B, Tonshoff B . Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?. Paediatr Drugs. 2010; 13(1):49-69. DOI: 10.2165/11538530-000000000-00000. View